Keywords
How to Cite
Abstract
Early detection of steatohepatitis in metabolically at-risk populations is less about finding “fatty liver” and more about identifying the smaller subgroup with clinically significant fibrosis, because fibrosis stage best predicts liver-related outcomes and determines who needs specialist management and closer surveillance. Liver biopsy remains the reference standard for defining steatohepatitis and staging fibrosis, but it is invasive and impractical for large-scale case finding. Therefore, modern strategies rely on targeted entry criteria to select high-yield risk groups and on stepwise non-invasive testing pathways to efficiently rule out advanced fibrosis in low-risk individuals while prioritizing confirmatory testing and referral for those at higher risk.
References
1. European Association for the Study of the Liver; European Association for the Study of Diabetes; European Association for the Study of Obesity. EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease: Executive Summary. Diabetologia, 2024, Vol. 67, No. 11, pp. 2375–2392. DOI: 10.1007/s00125-024-06196-3. PubMed+1
2. Rinella M. E., Lazarus J. V., Ratziu V., Francque S. M., Sanyal A. J., Kanwal F., et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology, 2023, Vol. 78, No. 6, pp. 1966–1986. DOI: 10.1097/HEP.0000000000000520. PubMed+1
3. Berzigotti A., Tsochatzis E., Boursier J., Castera L., Cazzagon N., Friedrich-Rust M., et al. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis: 2021 update. Journal of Hepatology, 2021, Vol. 75, No. 3, pp. 659–689. DOI: 10.1016/j.jhep.2021.05.025. EASL-The Home of Hepatology.+1
4. Rinella M. E., Neuschwander-Tetri B. A., Siddiqui M. S., Abdelmalek M. F., Caldwell S., Barb D., et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology, 2023, Vol. 77, No. 5, pp. 1797–1835. DOI: 10.1097/HEP.0000000000000323. PubMed+1
5. Sterling R. K., Duarte-Rojo A., Patel K., Asrani S. K., Alsawas M., Dranoff J. A., et al. AASLD Practice Guideline on imaging-based noninvasive liver disease assessment of hepatic fibrosis and steatosis. Hepatology, 2025, Vol. 81, No. 2, pp. 672–724. DOI: 10.1097/HEP.0000000000000843. PubMed+1
6. Newsome P. N., Sasso M., Deeks J. J., Paredes A., Boursier J., Chan W. K., et al. FibroScan–AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. The Lancet Gastroenterology & Hepatology, 2020, Vol. 5, No. 4, pp. 362–373. DOI: 10.1016/S2468-1253(19)30383-8.